First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC.
The FDA has granted a Breakthrough Therapy designation to the antibody-drug conjugate enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
Increases in resource use were not associated with improved survival or quality of care for patients with metastatic prostate cancer, but were associated with higher healthcare costs.
Proton radiation therapy offers some reduced toxicity over IMRT in patients under the age of 65 with prostate cancer, but its cost is nearly double.
The FDA is granting Priority Review for the expanded use of enzalutamide in nonmetastatic castration-resistant prostate cancer.
Differential methylation in CITED4, as measured in blood, appears to be a promising marker of bladder cancer susceptibility in women.
Abiraterone plus prednisolone/prednisone, or docetaxel, combined with ADT may be the most effective therapies for metastatic hormone-naive prostate cancer.
Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer
An 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy.
The first article in this two-part series will provide an overview of both past and present therapeutic vaccination strategies for the promotion of antitumor immunity against prostate cancer.
Alterations to DDR genes were associated with improved outcomes in patients with metastatic urothelial carcinoma who were treated with immunotherapy.